Investigators: Camille Gibson, Fiona McDonald, Glady Perez, Jan Jones, Jennifer Kent, Lisa Montgomery, Peter Richmond, Tanya Stoney
Project description
Respiratory Syncytial Virus (RSV) is a common virus that can cause serious respiratory illness in infants and young children. It is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in infants and young children, which can result in hospitalisation. Preterm infants are at particularly high risk of hospitalisation with an RSV infection.
There are no vaccines available to prevent RSV infection. Currently there is a medication to prevent RSV, but it is usually reserved for infants who have serious heart or lung disease, and some premature infants born at less than 28 weeks gestation. This study is being done to evaluate how effective a new medication (called MEDI8897) is at preventing serious respiratory illness caused by RSV in preterm infants.
Partners:
- AstraZeneca / MedImmune